Medacta: New Medical Director; 140% Sales Growth!

S. Raymond Golish, M.D., Ph.D., M.B.A., a veteran clinician-scientist, has been named as the new Medical Director of the Medacta USA Spine Division. The company is also announcing enormous growth, with its Spine Division experiencing more than 140% sales growth in 2016. According to the February 1, 2017 news release, this division “now boasts five consecutive quarters of 24% quarter-over-quarter growth. Last year, the Division increased its customer base by 105% and added more than 40 new field agents selling its products in the U.S.”

“Dr. Golish is a fellowship-trained spinal surgeon, medical device and data scientist, and experienced healthcare administrator and executive. He currently acts as Medical Director of Spinal Surgery and of Clinical Trials at Jupiter Medical Center (Jupiter, Florida) and is a practicing spinal surgeon at Florida Spine Center in Palm Beach, Florida. He serves as Chairman of the American Academy of Orthopaedic Surgeons (AAOS) Biomedical Engineering Committee and Chairman and Director of the Board for the Research Committee of the North American Spine Foundation. From 2012 to 2016, he was a voting member on the U.S. Food and Drug Administration’s Orthopaedic and Rehabilitation Devices Panel. Dr. Golish received his Ph.D. and M.D. from the University of California, Los Angeles in 2002 and 2004, respectively. He completed his spinal surgery fellowship at Stanford University in 2010 and received his M.B.A. from Duke University in 2013.”

“With his diverse experience as a surgeon, medical data scientist and expert in U.S. regulatory affairs, Dr. Golish will be an important addition to the Medacta spine team as it continues to introduce methodical, thoughtful and evidence-based innovations,” said Francesco Siccardi, executive vice president of Medacta International. “His steadfast dedication to patient safety and the role that medical device innovation can play in improving life aligns well with our ideals at Medacta, and we are thrilled to have him on board as we look to meet our ambitious growth targets in the year ahead.”

“Medacta’s key differentiator is its unique corporate culture, which focuses on excellence in patient care, quality, evidence and innovation in a way that moves the field forward while keeping safety paramount,” said Dr. Golish. “It’s an exciting time for Medacta as a whole, but especially for its Spine Division, which experienced transformative growth in 2016 and is poised to meet or even exceed upon the bold growth targets set for 2017.”
Asked about this growth, Medacta USA U.S. Vice President of Sales, Spine Division David Sponsel told OTW, “I attribute our Spine Division growth to three primary factors: the addition of more sales leaders, product managers, and sales professionals to our team; three new product launches; and our world-class learning centers, where we trained over 60 surgeons in 2016.”

“Over the next 6-12 months, we plan to continue building upon our sales leadership and product management teams, while adding 40+ direct and independent sales agents. We’re also maintaining a strong focus on supporting and strengthening our surgeon consultants and educators so we can help our current and prospective surgeon partners achieve clinical excellence when using Medacta products.”